Although pharmacologic options for Tourette syndrome have historically been limited by adverse effects, ongoing research is beginning to shift that landscape. At the same time, science alone cannot address every challenge faced by those living with the condition -- read about the lived experience in Part 1. This second installment explores both the promise of a novel therapeutic approach and the equally powerful role of education, disclosure, and social acceptance in improving quality of life.
Emerging Pharmacologic Approaches for Tourette Syndrome
The prevalence of adverse effects is why many individuals with Tourette syndrome are encouraged by novel therapies that could change that trajectory. Ecopipam is the first dopamine D1-receptor antagonist under evaluation as a potential treatment for Tourette syndrome. In a randomized trial published in 2023 involving 153 children and adolescents with Tourette syndrome, patients receiving ecopipam demonstrated a statistically significant reduction in the Yale Global Tic Severity Score -- Total Tic Score (YGTSS-TTS) at 12 weeks compared with those receiving placebo (mean reduction of 10 points vs. 6.5 points, respectively). Of note, the upper bound of the confidence interval approached zero, tempering these otherwise statistically significant findings.
To further assess long‑term safety and efficacy, investigators initiated a 12-month open-label extension. Across both the randomized phase and the extension, ecopipam was not associated with changes in BMI, blood lipid levels, glycated hemoglobin (HbA1c), or blood pressure. Given that metabolic adverse effects such as weight gain, dyslipidemia, and others are common with currently available pharmacologic treatments, these findings are particularly encouraging.
Importantly, ecopipam is not without risk. Approximately one-third of participants experienced at least one treatment-related adverse event, including anxiety (6.6 percent of patients), depression (5.6 percent of patients), and insomnia (5.8 percent of patients). One participant reported a serious adverse event involving new-onset obsessive thoughts. While these effects are concerning, they are not unique to this new class of D1-receptor antagonists and overlap with the adverse events observed with established dopamine D2-receptor antagonists.
With respect to efficacy, the open-label extension demonstrated a mean reduction of 17.3 points on YGTSS-TT from baseline at 12 months, corresponding to a clinically meaningful 40 percent improvement. Although these long-term results lack placebo control, they suggest a potentially durable benefit that warrants further validation. A phase 3 clinical trial evaluating the risk of symptom relapse has recently been completed, with results pending publication.
Overall, ecopipam shows promise as a medical treatment for Tourette syndrome that offers comparable efficacy to current medications, but with a more favorable safety profile. Unfortunately, effective medical treatments for complex conditions such as Tourette syndrome remain limited. While early data from novel therapies are encouraging and worth pursuing, pharmacologic advances alone are unlikely to address the full burden of Tourette syndrome.
Reducing Stigma of Tourette Syndrome Through Education and Awareness
For many neurodevelopmental disorders, including Tourette syndrome, reductions in stigma through education and awareness can often have a greater impact on quality of life than symptom control alone. Misunderstanding and stigma often contribute to social isolation, discrimination, and emotional distress, which can exacerbate symptoms and impair functioning. Addressing these barriers can meaningfully improve daily functioning, self-esteem, and community inclusion.
My own experience illustrates this dynamic. After trying different medications during my first year of college, my doctor decided to shift our approach to management. He knew a major source of my distress and anxiety was rooted in attempts to mask or hold in my tics in certain social situations, even around my closest friends and extended family. Although no one made me feel this way, fear of drawing attention led to constant suppression, causing a self-perpetuating cycle of social anxiety, which only made my symptoms worse and made them harder to mask.
Rather than escalating medical therapy to try to stop my symptoms, my physician encouraged me to disclose my diagnosis to my close friends. I decided to give it a shot and was relieved to learn that everyone I told was already aware of my tics and accepted them as part of who I was without judgment. In fact, they had been habituated and barely even noticed my tics anymore.
Over time, I became comfortable telling new people, including entire classes, and accessed academic accommodation through the student disability center. I received permission to take all my exams in a separate room so I would not worry about distracting anyone else and could focus on the exam material. These non-medical interventions, coupled with a dedicated support system, without a doubt made the greatest positive impact on my quality of life.
Relief from not having to constantly attempt to suppress and mask my tics or worry about what people around me might think when they saw or heard me performing a tic lifted a huge weight off my shoulders that allowed me to navigate the world with less social anxiety, higher self-esteem, and more confidence. Advocacy organizations such as the Tourette Association of America play a crucial role in advancing this kind of awareness, while also supporting research efforts that improve clinical care.
Ultimately, my ability to reflect positively on the role that Tourette syndrome has played in shaping my empathy and career trajectory in biomedical research, neuroscience, and scientific communication would not have been possible without acceptance, both from myself and from others. That acceptance was fostered not by medication alone, but by understanding.
Bottom Line
The future of Tourette syndrome care lies at the intersection of scientific innovation and social understanding. Novel therapies such as ecopipam offer legitimate hope for safer symptom management, but they represent only part of the solution. Education, openness, and acceptance can alleviate burdens that no medication can fully address. Together, continued research and a more informed public offer the most meaningful path forward for individuals living with Tourette syndrome.
References
Pediatrics. 2023 Feb 1;151(2):e2022059574
Mov Disord Clin Pract. 2025 Aug;12(8):1157-1166
For information on the Tourette Association of America, visit https://tourette.org/.
